New hope for stomach cancer: drug combo targets tough tumors
NCT ID NCT07362186
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study tests whether a new drug (LM-108) combined with toripalimab works better than standard chemotherapy (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CCR8-positive). About 400 adults whose cancer has worsened after first treatment will be randomly assigned to one of the two options. The main goal is to see if the combination helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC GC AND GCJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.